Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for diabetes mellitus, noninsulin-dependent, 3 has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE3. Research is primarily industry-sponsored.
105 publications have been identified in PubMed for diabetes mellitus, noninsulin-dependent, 3. Kisho has analyzed 73 by research type. Research spans Epidemiology / Natural History (38%), Review / Meta-Analysis (32%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 28 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 10:41 AM UTC
Online Mendelian Inheritance in Man
Research summaries | 23 | 32% |
Clinical study results | 9 | 12% |
Laboratory research | 8 | 11% |
Testing and diagnosis research | 3 | 4% |
Patient case studies | 2 | 3% |
Wang H (2026). [PMID: 41713504](https://pubmed.ncbi.nlm.nih.gov/41713504/). *Diabetes Res Clin Pract*. [Review / Meta-Analysis]
Liu H (2025). [PMID: 39748566](https://pubmed.ncbi.nlm.nih.gov/39748566/). *Ann Med*. [Review / Meta-Analysis]
Satheesh G (2025). [PMID: 40790364](https://pubmed.ncbi.nlm.nih.gov/40790364/). *Metabolomics*. [Epidemiology / Natural History]
Cheng W (2025). [PMID: 41341136](https://pubmed.ncbi.nlm.nih.gov/41341136/). *Front Endocrinol (Lausanne)*. [Clinical Trial Publication]
Xu EJ (2025). [PMID: 40613016](https://pubmed.ncbi.nlm.nih.gov/40613016/). *Kidney Med*. [Review / Meta-Analysis]
Wang G (2025). [PMID: 39639837](https://pubmed.ncbi.nlm.nih.gov/39639837/). *Diabetes Obes Metab*. [Review / Meta-Analysis]
He W (2025). [PMID: 40332561](https://pubmed.ncbi.nlm.nih.gov/40332561/). *Acta Diabetol*. [Review / Meta-Analysis]
Li XM (2025). [PMID: 41402782](https://pubmed.ncbi.nlm.nih.gov/41402782/). *Cardiovasc Diabetol*. [Basic Science / Preclinical]
Huang X (2025). [PMID: 41098588](https://pubmed.ncbi.nlm.nih.gov/41098588/). *Front Endocrinol (Lausanne)*. [Epidemiology / Natural History]
Zhong X (2025). [PMID: 41063371](https://pubmed.ncbi.nlm.nih.gov/41063371/). *Diabetes Obes Metab*. [Epidemiology / Natural History]
AI-curated news mentioning diabetes mellitus, noninsulin-dependent, 3
Updated Feb 2, 2026
Novo Nordisk's CagriSema demonstrates superior blood sugar and weight reduction compared to Wegovy in a recent diabetes trial. However, it may face challenges competing against Eli Lilly's Zepbound in the obesity market.
The CDC has released the latest National Diabetes Statistics Report, providing updated statistics on diabetes prevalence and impact. This periodic publication is crucial for informing health policy and resource allocation.
The CDC reports that the Southeast, Appalachia, and certain tribal lands have the highest rates of obesity and diabetes in the U.S. This data highlights significant health disparities that may require targeted public health interventions.
The CDC's 32nd Annual Diabetes Conference will address innovative strategies for diabetes prevention and control. The event will include various sessions aimed at practitioners and leaders in the field.